Our earlier article on optogenetics explored an experimental way of giving surviving cells in the retina a new sensitivity to light. For people who have lost the eye’s natural light detectors, it offers a possible route back to some useful vision. The research here concerns a different disease, but returns to a question many of us have about our eyes: as sight deteriorates, how much might one day be recovered?
Glaucoma makes that question particularly urgent. A leading cause of irreversible blindness, it can gradually damage vision without announcing itself through pain or obvious blur. Current treatments can slow or prevent further loss, but cannot replace the nerve cells already lost. The scale is substantial: a widely cited global analysis projected that approximately 112 million people aged 40–80 would have glaucoma by 2040.¹,²
Life Biosciences, the biotechnology company co-founded by Harvard geneticist David Sinclair, is testing whether some surviving, damaged nerve cells could regain function. Its experimental treatment, ER-100, uses a process called epigenetic reprogramming, and the company announced its first early human observations on 8 October 2026. Before explaining that approach, it helps to understand what glaucoma damages, and why.³

What glaucoma damages
Glaucoma injures the eye’s connection to the brain. Within the retina, the light-sensitive tissue lining the back of the eye, retinal ganglion cells collect processed visual information. Their long nerve fibres gather into the optic nerve, which carries those signals to the brain. As these cells and fibres deteriorate, parts of the visual field become less sensitive or disappear, even while the central vision used for reading may still seem clear.⁴
Eye pressure is the most important risk factor that treatment can modify. At the front of the eye, a clear fluid called aqueous humour is continually produced behind the iris, flows through the pupil, and drains mainly through a fine filtering tissue where the iris meets the cornea. This is separate from the vitreous gel in which floaters form. When drainage becomes less efficient, pressure can rise throughout the eyeball. It need not rise continuously: it can settle at an elevated level or fluctuate over the day, exposing a vulnerable nerve to repeated or sustained stress.⁵,⁶
Why should a drainage problem at the front injure a nerve at the back? The nerve fibres leave through a delicate supporting structure called the lamina cribrosa. Pressure can deform this tissue and strain the fibres passing through it, disrupting the transport of materials and survival signals along them. Blood supply and cellular energy production can also become compromised. Over time, vulnerable ganglion cells lose function and may die, leaving a permanent gap in the visual information reaching the brain.⁷

Aqueous humour drains at the front; the optic nerve is vulnerable to pressure at the back.
The different forms, and who is at risk
The names of the main forms describe what is happening to the drainage route. In open-angle glaucoma, the angle between the iris and cornea remains open, but fluid encounters increased resistance as it drains. This is the most common form in the UK and US, and it usually develops slowly. In angle-closure glaucoma, the iris obstructs access to that drainage tissue. Closure can develop gradually or cause a sudden, dangerous rise in pressure.¹,⁸
Normal-tension glaucoma is a form of open-angle disease in which damage occurs despite pressure readings within the usual population range. A nerve’s susceptibility matters as well as the pressure acting on it; conversely, some people have high pressure without glaucoma. Heredity cuts across these categories: family history raises risk, while some rare childhood and early-onset forms have particularly strong genetic causes. A person can have inherited susceptibility and normal-tension glaucoma at the same time.⁴,⁷,⁸
Risk rises with age and is higher with an affected parent or sibling. African and Caribbean ancestry is associated with greater open-angle risk; Asian ancestry and long-sightedness are associated with angle closure. Short-sightedness, diabetes, previous eye injury, and steroid exposure can also matter, depending on the form. Steroid eye drops, tablets, inhalers, and even creams around the eyelids deserve mention to the eye clinic; do not stop a prescribed medicine without advice.¹,⁹
Blood pressure has a more complicated relationship with glaucoma than “high is bad, low is good”. Hypertension is associated with increased risk in some studies, while excessively low pressure, particularly overnight, may reduce blood flow to an already vulnerable optic nerve. Sleep apnoea and insomnia have also been associated with glaucoma, although those links do not establish that treating sleep problems prevents it. Discuss persistent snoring, breathing pauses, or daytime sleepiness with a clinician, and let your glaucoma specialist know about blood-pressure treatment.⁷,¹⁰,¹¹
Because the common forms can remain unnoticed, an eye examination is more useful than waiting to see whether your vision changes. Sudden severe eye pain, a red eye, blurred vision, or haloes around lights, especially with nausea, require emergency assessment. These can signal an acute angle-closure attack.¹
Could a damaged nerve cell work better again?
The difficulty with restoring vision is that lost retinal ganglion cells are not naturally replaced. Yet a surviving cell can become dysfunctional before it dies. That distinction gives researchers a potential opening: could improving the condition of those remaining cells recover some of the visual function they have ceased to provide? Reprogramming is an attempt to reach that surviving capacity, rather than a way of bringing dead neurons back to life.⁴,¹²
Its history begins well before the current glaucoma trial. In 2006, Kazutoshi Takahashi and Shinya Yamanaka showed that four gene-regulating proteins could turn mature mouse cells into stem-like cells capable of developing into many cell types. That discovery overturned the assumption that a cell’s developmental state was fixed. A later question was whether a more limited intervention could restore useful properties without erasing the cell’s identity. In 2016, Alejandro Ocampo and colleagues reported that brief, repeated activation of those factors improved several age-related features in mice.¹³,¹⁴
For vision, the aim is to keep a ganglion cell a ganglion cell, while helping it function more effectively. This brings us to epigenetics: the systems that regulate which parts of a cell’s DNA are used, and how actively. Chemical marks on DNA and its associated proteins help organise that activity. Sinclair’s work advances the hypothesis that disruption of these patterns contributes to ageing, and that restoring aspects of their organisation could restore function. It is a testable account of part of ageing biology, not an established explanation for all ageing or all glaucoma.¹⁵
In the 2020 Nature study, Yuancheng Lu, Sinclair, and colleagues made mouse retinal ganglion cells produce three of the reprogramming proteins: OCT4, SOX2, and KLF4, together called OSK. They reported changes towards more youthful gene-activity patterns, nerve-fibre regrowth after experimental injury, and improved visual function in mice with experimentally induced glaucoma. These cells were a purposeful target: they are the neurons glaucoma damages, and their activity provides measurable tests of whether a change in cellular regulation produces a change in vision.¹⁵
ER-100 takes that principle into human testing. A single injection into the eye delivers genetic instructions using a modified viral carrier. For eight weeks, participants take oral doxycycline, which activates a built-in switch so that cells produce the OSK proteins. The intended effect is a controlled change in gene activity within surviving ganglion cells. Researchers must establish that this can improve function while preserving cell identity: reprogramming too far can cause harmful changes, including tumour formation in experimental systems. The switch is a control mechanism, not proof that every risk has been eliminated.¹⁴,¹⁶,¹⁷

What the first human observations mean
On 8 October 2026, Life Biosciences reported results through day 56 in three people with open-angle glaucoma. Two showed preliminary improvements on visual-field testing, which measures how dim a light a person can detect at different locations. No serious adverse events or dose-limiting toxicities were reported, although other events occurred, attributed by the company to the procedure, steroids, or pre-existing conditions. The independent safety board recommended proceeding to a higher dose.³
That is a reason to follow the trial closely, rather than a demonstration that sight has been restored. This first-stage, open-label study primarily assesses safety: everyone knows treatment is being given, and there is no control group. Visual-field results fluctuate and can improve with practice. Larger controlled studies and longer follow-up will need to establish whether an improvement is real, lasts, and matters in everyday life. Neither a better visual-field test nor a more youthful molecular marker would, by itself, establish reversal of human ageing.³,¹⁶
There is another practical question: what happens if the nerve’s environment remains damaging? Stem-cell biologist Paul Knoepfler has highlighted that ER-100 is not designed to lower eye pressure. Even if a surviving cell recovers function, it still needs protection from the stresses that injured it. A successful restorative treatment would therefore need to fit alongside glaucoma management, not make pressure control redundant.¹⁷
And how does this differ from optogenetics? In the approach covered in our optogenetics article, for retinitis pigmentosa, the rods and cones that normally detect light have been lost. Genetic instructions give surviving ganglion cells light-sensitive proteins, allowing them to detect specially delivered light and bypass the missing detectors. That still relies on a usable nerve pathway to the brain. ER-100 addresses dysfunction in the ganglion cells themselves, aiming to improve their existing role in carrying visual information. Both use gene-delivery tools, but they address different failures in the visual system.¹⁵,¹⁸
Protecting sight with the treatments available today
For someone with glaucoma, the immediate priority is a workable plan to lower eye pressure and check whether damage is progressing. Lowering pressure can help even in normal-tension disease. The target is individual: a reading within the usual range may still be too high for a particular nerve.⁴,¹⁹
Eye drops and laser treatment improve the fluid balance. Prescription drops reduce fluid production or improve drainage. Selective laser trabeculoplasty, or SLT, treats the drainage tissue and is a first-line option for suitable people with newly diagnosed, non-advanced open-angle glaucoma. Some people still need drops afterwards. If a prescription is irritating, difficult to use, or frequently missed, tell the clinic: treatment needs to fit the person who must keep using it.¹⁹,²⁰
Surgery can provide a stronger drainage route when needed. Trabeculectomy and drainage implants are important options for advanced or progressing disease; less invasive procedures suit selected patients, sometimes alongside cataract surgery. For angle closure, laser iridotomy creates a small opening in the iris, while lens extraction can open up the crowded drainage angle. Choosing a procedure depends on the eye’s anatomy and the reduction in pressure required.¹⁹,²¹
Follow-up shows whether the plan is working. Pressure measurements, optic-nerve imaging, and visual-field tests answer different questions, so a reassuring pressure reading cannot replace the other checks. Keep treatment and appointments even when sight feels unchanged. Exercise and appropriate care for diabetes, blood pressure, and sleep disorders support wider health; changes to prescribed medicines or sleep-apnoea treatment should be discussed with the relevant clinician.¹,¹⁰,¹⁹
Could nutrition make nerve cells more resilient?
Pressure control addresses a major source of injury, but researchers are also asking whether nutrition can help ganglion cells withstand it. These neurons need energy to maintain their electrical activity and transport materials along their fibres. Mitochondria, the cell’s energy-producing structures, can become impaired, while reactive oxygen molecules damage proteins, membranes, and DNA. Oxidative stress has also been found in the drainage tissue, where damage may further impair fluid outflow. These processes interact with mechanical strain, blood supply, and inflammation; glaucoma is not simply an antioxidant deficiency.¹²,²²
This creates several nutritional research targets: energy metabolism, cell membranes, and antioxidant defences. It also explains why a useful early result can take different forms. Improving a retinal electrical response, lowering pressure, and preventing years of visual-field loss are distinct achievements. A promising result in one does not automatically establish the others.
Nicotinamide, a form of vitamin B3, is among the most actively studied candidates. It helps the body make NAD+, a molecule essential to energy metabolism. A randomised crossover trial in 57 people with treated glaucoma reported improved inner-retinal electrical responses. A separate small placebo-controlled trial of nicotinamide with pyruvate found improvement at more visual-field test locations, although not all overall field measures improved. Long-term protection against sight loss remains under investigation.²³,²⁴
The trial doses are far above ordinary nutritional requirements, and high-dose nicotinamide can cause serious liver injury. The American Academy of Ophthalmology and American Glaucoma Society advise medical oversight and monitoring; people with liver disease should not take it for this purpose. Nicotinamide, also called niacinamide, is not interchangeable with niacin. Discuss it with a glaucoma specialist before considering high-dose use.²⁵
Citicoline is being studied for support of nerve-cell membranes and signalling. It participates in the production of phosphatidylcholine, a major membrane lipid. Small human studies, including a 12-month placebo-controlled trial of an oral solution, have reported improvements in electrical responses from the retina and visual pathway alongside conventional treatment. Whether that reliably preserves everyday vision over years remains an open question.²⁶
Pycnogenol®, a branded French maritime pine-bark extract, also has human research. Much concerns Mirtogenol®, a combination with bilberry extract. In a 24-week study of 79 people with raised eye pressure, researchers reported pressure reductions with the combination, including an additional effect alongside latanoprost drops. These participants had ocular hypertension without established glaucoma damage. The study cannot isolate pine bark’s contribution or demonstrate that the supplement prevents glaucoma or blindness.²⁷
Other candidates include ginkgo biloba, which has conflicting visual-field findings; coenzyme Q10, whose research includes eye drops combined with vitamin E; and saffron, with a small one-month oral trial showing an additional pressure reduction. The preparation and route matter: results from a combined eye drop cannot establish the effect of an oral capsule.²⁸,²⁹,³⁰
What about the ingredients in Clearer®?
A customer asked whether Clearer®’s ingredients might be useful for glaucoma. There is a biological reason to ask: different eye tissues share vulnerabilities to oxidative stress and age-related cellular damage, so an ingredient investigated for one tissue may merit investigation in another. The next step is to examine research in glaucoma itself, where nerve survival and pressure regulation introduce very specific demands.
Grape-seed proanthocyanidins have been studied in a mouse model of glaucoma, with reported reductions in oxidative stress and greater ganglion-cell survival. Hesperidin, a citrus flavonoid present in bitter orange, has been included in a human study of 30 people with normal-tension glaucoma, alongside crocetin and tamarind. Some oxidative-stress markers improved in a higher-stress subgroup, but the main marker did not improve across the whole group. That uncontrolled combination study did not demonstrate preserved vision, or identify hesperidin’s effect on its own.³¹,³²
Many people take Clearer® primarily for floaters and vitreous health, but its nutritional scope is broader. Lutein and zeaxanthin contribute to macular pigment, while vitamin C participates in antioxidant defence, including within the lens. These nutrients also have systemic roles: vitamin C supports collagen formation in skin and joint cartilage, and neurotransmitter synthesis; carotenoids have been investigated for brain function and skin responses. Their biology extends beyond the eye, although ingredient research does not establish every benefit for the finished formula.³³,³⁴,³⁵,³⁶,³⁷
At the same time, we will not present Clearer® as a universal answer to every eye concern. One of our core beliefs is that eye nutrition needs to be condition-specific: the most useful nutrients vary with the tissue, the underlying problem, and the evidence. Clearer® contains grape-seed extract and bitter orange, but has not been shown to treat glaucoma. For someone with the condition, supplementation belongs in a discussion alongside specialist care and effective pressure control.
The possibility of recovering sight gives us another reason to protect the nerve cells on which that recovery would depend. While research establishes what might be recoverable, finding glaucoma early and treating it consistently remain the strongest foundations for preserving what we see.
Filed under
Frontiers of science







